FTI Consulting Crumbles on iManage Deal
FTI Consulting, Inc. (NYSE: FCN) today announced that the firm’s Technology segment has entered into a teaming agreement with iManage, the company “dedicated to Making Knowledge Work™”. This alliance will support FTI Technology’s Corporate Legal Operations practice in providing clients with cloud-based, fit-for-purpose solutions to solve legal department and law firm knowledge work-related challenges.“The majority of legal departments anticipate an increase in their use of technology platforms that support automation and knowledge management for their organizations,” said Managing Director Mike Ferrara. “As clients look to capitalize on their existing investments in document management or unlock new opportunities through artificial intelligence capabilities, our global team brings expertise and collaboration with iManage to support technology assessment, road mapping, implementation, adoption and more.”Serving large, global enterprises and law firms, iManage enables legal teams to manage high-value legal content more efficiently and securely, while empowering counsel to collaborate and meet complex document management demands across their organization. Through this alliance, FTI Technology will help clients implement knowledge management and collaboration workflows and systems that enhance productivity, deliver insight and improve efficiency for counsel.FCN shares slumped $5.53, or 2.8%, to $189.82.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


